Financial Personal
Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma
EfficAPSI is a real-world study with the largest number of patients follow-up to date in the field of allergen immunotherapy (AIT).1 The rigorous methodology used in this study provides important insights about Stallergenes Greer SLIT-liquid as aller
BAAR, Switzerland -- Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online ( https://doi.org/10.1016/j.lanepe.2024.100915) and will be available in print at a later date. Read More
Related
Share this page
Guest Posts by Easy Branches